Amgen discusses the future with analysts

Sure, we've got trouble, says Amgen CEO Kevin Sharer. But we can handle it. That's the bottom line from a Monday chat with investors, many of whom are more than a little worried by today's FDA panel meeting on anemia drugs. Amgen is out to counter a Medicare decision to curb the use of Aranesp and other anemia drugs. And the company, which has recently announced a major restructuring, can "hack it," he says reassuringly. Still, the biotech giant notes that it is besieged by some critical problems.

"We're a company that obviously has more than our share of challenges right now," Sharer told analysts. "We have a new reality in the business and it's not a completely predictable dynamic."

- see Amgen's release on the FDA anemia drug meeting
- check out the AP report for more on Amgen's discussion with analysts

ALSO: Throw a bunch of pharma execs into a room with financial analysts, and what do you get? Almost unmitigated hope. Report

Related Articles:
Amgen ups lobbying efforts. Report
New Medicare cap on anemia drugs could hammer Amgen. Report
Amgen makes big workforce, budget cuts. Report
Amgen in crisis? Not us, says CEO Sharer. Report
Amgen stock slips as anemia drug concerns rise. Report 

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.